Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption

ChemMedChem. 2011 Jul 4;6(7):1258-68. doi: 10.1002/cmdc.201000540. Epub 2011 Mar 15.

Abstract

A number of matrix metalloproteinases (MMPs), proteins important in the balance of bone remodeling, play a critical role both in cancer metastasis and in bone matrix turnover associated with the presence of cancer cells in bone. Here, we report the synthesis and biological evaluation of a new class of MMP inhibitors characterized by a bisphosphonate function as the zinc binding group. Since the bisphosphonate group is also implicated in osteoclast inhibition and provides a preferential affinity to biological apatite, the new molecules can be regarded as bone-seeking medicinal agents. Docking experiments were performed to clarify the mode of binding of bisphosphonate inhibitors in the active site of MMP-2. The most promising of the studied bisphosphonates showed nanomolar inhibition against MMP-2 and resulted in potent inhibition of osteoclastic bone resorption in vitro.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Bone Density Conservation Agents / chemistry*
  • Bone Density Conservation Agents / therapeutic use
  • Bone Density Conservation Agents / toxicity
  • Cell Line, Tumor
  • Computer Simulation
  • Diphosphonates / chemistry*
  • Diphosphonates / therapeutic use
  • Diphosphonates / toxicity
  • Humans
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase Inhibitors*
  • Matrix Metalloproteinases / metabolism
  • Protease Inhibitors / chemistry*
  • Protease Inhibitors / therapeutic use
  • Protease Inhibitors / toxicity
  • Structure-Activity Relationship

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • Matrix Metalloproteinases
  • Matrix Metalloproteinase 2